Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

PLYMOUTH, Mass., January 13, 2025--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

In pancreatic cancer, pelareorep previously demonstrated a strong efficacy signal when administered with gemcitabine, nab-paclitaxel and atezolizumab. Our new safety data indicate its ability to also ...

JD SPORTS reported pre-tax profits of £917.2 million (€1.1 billion) in 2023 and hoped for 2024 earnings of £1 billion (€1.19 ...

The stock market can be a scary place for those who aren’t prepared. Our writer outlines three ways we might avoid getting caught out.

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...

Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning ...

GSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. EU regulators have approved the ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...